SCHEMBL19975445

SCHEMBL19975445

COc1ccccc1NC(c1ccccc1)C(O)C(=O)NCc1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.48
CTSD P07339 1/20 0.47
APEX1 P27695 1/20 0.45
L3MBTL1 Q9Y468 3/20 0.44
ALDH1A1 P00352 3/20 0.44
NPSR1 Q6W5P4 3/20 0.44
LMNA P02545 3/20 0.44
TDP1 Q9NUW8 1/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PLA2G1B P04054 1/20 0.44
HTT P42858 1/20 0.44
ATG4B Q9Y4P1 1/20 0.44
MASP2 O00187 1/20 0.43
NR3C2 P08235 2/20 0.43
ADAM17 P78536 1/20 0.42
KDM4E B2RXH2 1/20 0.42
CYP3A4 P08684 1/20 0.42
GAA P10253 1/20 0.42
ALOX15 P16050 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19974969 0.88 MAPT (0.51) MAPTCTSDAPEX1L3MBTL1ALDH1A1
SCHEMBL19975448 0.85 MAPT (0.48) MAPTCTSDAPEX1L3MBTL1ALDH1A1
SCHEMBL19975164 0.85 MAPT (0.46) MAPTCTSDAPEX1L3MBTL1ALDH1A1
SCHEMBL19975302 0.83 MAPT (0.47) MAPTCTSDAPEX1L3MBTL1ALDH1A1
SCHEMBL19974733 0.79 CTSD (0.48) MAPTCTSDAPEX1L3MBTL1ALDH1A1
SCHEMBL19974682 0.78 CTSD (0.51) MAPTCTSDAPEX1L3MBTL1ALDH1A1
SCHEMBL19974869 0.78 MAPT (0.48) MAPTCTSDAPEX1L3MBTL1ALDH1A1
SCHEMBL19975063 0.78 MAPT (0.48) MAPTCTSDAPEX1L3MBTL1ALDH1A1
SCHEMBL19975300 0.78 CTSD (0.47) MAPTCTSDAPEX1L3MBTL1ALDH1A1
SCHEMBL19974677 0.77 MAPT (0.51) MAPTCTSDAPEX1L3MBTL1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
CN-110062753-A Antiviral compounds 哈普洛根有限责任公司 2019-07-26 CN disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C MAPT 4561/4885CTSD 922/4885APEX1 3061/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C MAPT 4673/4885CTSD 1046/4885APEX1 2716/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C MAPT 4561/4885CTSD 922/4885APEX1 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.